Ring Therapeutics

About:

Ring Therapeutics is a gene therapy company focused on discovering and developing programmable genetic medicines.

Website: http://www.ringtx.com

Twitter/X: ring_tx

Top Investors: Alexandria Venture Investments, Invus, T. Rowe Price, UPMC Enterprises, Partners Investment

Description:

Ring Therapeutics is a multi-product platform company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy. Founded by Flagship Pioneering, Ring is pioneering the first redosable and targetable gene therapy platform by harnessing the biology of the human commensal virome. The company is expanding the applications of gene therapy beyond gene replacement, enabling a much wider array of modalities and mechanisms to treat previously inaccessible diseases.

Total Funding Amount:

$254M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2017-01-01

Contact Email:

info(AT)ringtx.com

Founders:

Avak Kahvejian, Erica Weinstein, Noubar Afeyan

Number of Employees:

101-250

Last Funding Date:

2023-03-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai